Vision Bionics
Bionic eye, electrical prosthesis surgically implanted into a human eye in an effort to allow for the transduction of light (the change of mild from the surroundings into impulses the mind can procedure) in human beings who have sustained intense damage to the retina. Although the Argus II system allows human beings to determine light, movement and shapes, it does now not but repair sight to the extent some may wish. This problem is basically due to the reality that the cutting-edge implant has handiest 60 electrodes. To see clearly, you'll need about 1,000,000. The devices consist of micro-electrodes surgically positioned in or close to one eye, along the optic nerve (which transmits impulses from the attention to the mind), or within the brain. The micro-electrodes stimulate the elements of the visible machine nonetheless useful in someone who has lost their sight. The first patient to acquire a bionic eye became Grandfather Keith Hayman in 2009, according to the Association of Optometrists (opens in new tab). He became in his 20s while he became identified with retinitis pigmentosa and went blind several years later
Related Conference of Vision Bionics
20th World Congress on Biomarkers, Cancer Therapy & Clinical Research
7th Annual Congress on Biosimilars and Future Biotherapeutics
41st International Conference on Next-Gen Biotechnology and Applications
Vision Bionics Conference Speakers
Recommended Sessions
Related Journals
Are you interested in
- 3D Bioprinting & Regenerative Medicine - Biotechnology- 2025 (France)
- Advancements in Biosimilar Development Technologies - Biosimilars 2026 (France)
- Advances in Genomic Biotechnology - Biotechnology 2025 (Spain)
- AI in Drug Discovery - Biotechnology- 2025 (France)
- AI in Vaccine Development - Biotechnology- 2025 (France)
- AI-Powered Precision Medicine - Biotechnology- 2025 (France)
- Artificial Intelligence and Digital Tools in Biotherapeutics - Biosimilars 2026 (France)
- Bio-Cybernetics & Smart Implants - Biotechnology- 2025 (France)
- Biobetters: The Next Generation of Biologics - Biosimilars 2026 (France)
- Bioethics in Biotechnology 5.0 - Biotechnology- 2025 (France)
- Bioinformatics & Big Data - Biotechnology- 2025 (France)
- Biomedical Biotechnology - Biotechnology 2025 (Spain)
- Biopharmaceuticals and Biosimilars - Biotechnology 2025 (Spain)
- Biosimilar Market Access and Reimbursement Policies - Biosimilars 2026 (France)
- Biosimilars in Oncology and Autoimmune Diseases - Biosimilars 2026 (France)
- Biosimilars in Rare and Orphan Diseases - Biosimilars 2026 (France)
- Biotechnology and Global Health - Biotechnology 2025 (Spain)
- Biotechnology in Agriculture - Biotechnology 2025 (Spain)
- Biotechnology in Space - Biotechnology- 2025 (France)
- Blockchain for Biotech Data Security - Biotechnology- 2025 (France)
- Brain-Computer Interfaces & Neurobiotech - Biotechnology- 2025 (France)
- Clinical Trials & Comparability Studies for Biosimilars - Biosimilars 2026 (France)
- Collaborative Models in Biosimilar Development - Biosimilars 2026 (France)
- Computational and Systems Biology - Biotechnology 2025 (Spain)
- Cost-Effectiveness and Health Economics of Biosimilars - Biosimilars 2026 (France)
- CRISPR & Beyond - Biotechnology- 2025 (France)
- Environmental Biotechnology - Biotechnology 2025 (Spain)
- Evolving Trends and Innovations in Biosimilar Development and Access - Biosimilars 2026 (France)
- Formulation and Delivery Systems for Biologics - Biosimilars 2026 (France)
- Future Biotherapeutics: Cell and Gene Therapies - Biosimilars 2026 (France)
- Future of AgriTech - Biotechnology- 2025 (France)
- Future of Monoclonal Antibodies and Fusion Proteins - Biosimilars 2026 (France)
- Future Trends in Biotechnology - Biotechnology 2025 (Spain)
- Global Trends and Challenges in Biosimilar Adoption - Biosimilars 2026 (France)
- Immunogenicity Assessment and Risk Management - Biosimilars 2026 (France)
- Industrial Biotech & Smart Biofactories - Biotechnology- 2025 (France)
- Industrial Biotechnology - Biotechnology 2025 (Spain)
- Industrial Scale-Up and Bioprocessing - Biotechnology 2025 (Spain)
- Interchangeability and Substitution Policies - Biosimilars 2026 (France)
- Manufacturing and Quality Control of Biosimilars - Biosimilars 2026 (France)
- Marine Biotechnology - Biotechnology 2025 (Spain)
- Microbial Biotechnology - Biotechnology 2025 (Spain)
- Nanotechnology in Medicine - Biotechnology- 2025 (France)
- Patient and Physician Perspectives on Biosimilar Use - Biosimilars 2026 (France)
- Personalized Nutrition & Gut Microbiome - Biotechnology- 2025 (France)
- Pharmacovigilance and Post-Marketing Surveillance - Biosimilars 2026 (France)
- Quantum Computing in Biotech - Biotechnology- 2025 (France)
- Regulatory Pathways and Global Harmonization - Biosimilars 2026 (France)
- Smart Biomanufacturing - Biotechnology- 2025 (France)
- Stem Cell and Regenerative Medicine - Biotechnology 2025 (Spain)
- Sustainable Biotech Innovations - Biotechnology- 2025 (France)
- Synthetic Biology and Bioengineering - Biotechnology 2025 (Spain)
- Synthetic Biology: Reprogramming Life - Biotechnology- 2025 (France)
- The Future of Biotech Startups - Biotechnology- 2025 (France)
- Vaccine Development and Immunotherapy - Biotechnology 2025 (Spain)